IMARC Group, a leading market research company, has recently releases report titled “Cholera Vaccines Market Report by Vaccine Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), Product (Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus, and Others), End User (Hospitals and Clinics, Research and Academic Laboratories, and Others), and Region 2024-2032”, Offers a comprehensive analysis of the industry, which comprises insights on the global cholera vaccines market report.
How Big is the Cholera Vaccines Market?
The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032.
Industry Overview of Cholera Vaccines
Cholera is caused by intestine infection with the toxigenic bacterium Vibrio cholerae serogroup, resulting in an acute diarrheal illness. Its symptoms include watery diarrhea, vomiting, leg cramps, and rapid fluid loss leading to dehydration. The main source of contamination is water or food tainted by the feces of an infected person. Inadequate water treatment, lack of hygiene, and poor sanitation contribute to the occurrence and spread of cholera. Treatment involves promptly replenishing the lost fluids and salts through diarrhea. Oral rehydration solution (ORS), a premixed blend of sugar and salts combined with water, is an effective method. Various oral cholera vaccines (OCV), including Dukoral, Shanchol, and Euvichol, pre-qualified by the World Health Organization (WHO), are available for curing the disease.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample
What are the growth prospects and trends in the cholera vaccines industry?
The surge in the demand for cholera vaccines due to the escalating prevalence of cholera among populations worldwide. This factor, in conjunction with the thriving healthcare industry, serves as a pivotal driver for market growth. Additionally, prominent industry participants are dedicating their efforts to research and development endeavors, aiming to introduce an oral cholera vaccine.
The vaccine would utilize an avirulent culture of an El Tor vibrio strain obtained from a successfully tested water source on human volunteers. Simultaneously, the increasing awareness regarding the advantages of cholera vaccines among individuals is propelling market expansion. Furthermore, the market is experiencing a positive impact from the growing demand for Whole-cell V. cholerae O1 with a recombinant B-subunit vaccine, known for its high efficacy and long-lasting post-immunization protections.
Besides this, there is a rise in the usage of contaminated water in agriculture and horticulture practices across the globe. Moreover, the wide availability of oral vaccines through online and offline distribution channels, alongside mounting concerns regarding cholera outbreaks and the emergence of new strains, contribute to a favorable market outlook.
Leading Companies Operating in the Global Cholera Vaccines Industry:
- Astellas Pharma Inc.
- Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
- Emergent BioSolutions Inc.
- Eubiologics Co. Ltd.
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- PharmaChoice Canada Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Valneva SE
Cholera Vaccines Market Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- Killed Oral O1 and O139
Breakup by Product:
- Dukoral
- Shanchol
- Vaxchora
- Euvichol and Euvichol-Plus
- Others
Breakup by End User:
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
